Frontier Comms Parent Inc Bolsa (NASDAQ: FYBR)

Frontier Comms Parent Inc (NASDAQ:FYBR) Bolsa

Frontier Communications

Frontier Communications Parent Inc is a communications and technology provider offering broadband services. The company provides voice services, including data-based voice over Internet protocol (VoIP) and unified communications as a service (UCaaS), as well as long-distance and voice messaging services, to consumer and business customers in all its markets.

Frontier Communications Parent, Inc. - Common Stock

Frontier Communications Parent Inc

Macro Economic Events

News

Politics

Legal

Global

Economics

General

U.S. FCC Announces New Investigation Into China State-Aligned Entities

RBC Capital analyst Ryland Conrad maintains Prestige Consumer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBH#NYSE">PBH</a>) with a Sector Perform and raises the price target from $96 to $97.

Price Target

Analyst Ratings

RBC Capital Maintains Sector Perform on Prestige Consumer, Raises Price Target to $97

RBC Capital analyst Gregory Renza maintains Verastem (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTM#NASDAQ">VSTM</a>) with a Outperform and lowers the price target from $16 to $14.

VSTM

RBC Capital Maintains Outperform on Verastem, Lowers Price Target to $14

<a href="https://www.cnbc.com/2025/03/21/zepbound-copycats-tirzepatide-compounding-online-fda-ban.html">https://www.cnbc.com/2025/03/21/zepbound-copycats-tirzepatide-compounding-online-fda-ban.html</a>
<ul>
<li>Compounding pharmacies were largely supposed to stop making versions of tirzepatide this week, but it's still available on some popular websites like Amble, EllieMD, Willow and Mochi Health.</li>
<li>Pharmacies were able to make copycat versions of Eli Lilly's Zepbound and Mounjaro while the drugs were in shortage. But the FDA declared the shortage over late last year.</li>
<li>Mass compounding of Novo Nordisk's semaglutide — the active ingredient in Wegovy and Ozempic — is supposed to stop by the end of May.</li>
</ul>
This week was supposed to mark the end of <a href="https://www.cnbc.com/2024/12/24/fda-zepbound-shortage-impact-compounding-pharmacies-patients.html">compounding pharmacies</a> making copycat versions of <a href="https://www.cnbc.com/quotes/LLY/">Eli Lilly</a>'s weight-loss drug <a href="https://www.cnbc.com/2024/12/04/eli-lilly-zepbound-causes-more-weight-loss-than-novo-nordisk-wegovy-trial.html">Zepbound</a> and its diabetes drug Mounjaro. Online, it doesn't look like much has changed.&nbsp;
Popular websites like Amble, EllieMD, Willow and Mochi Health are all still advertising versions of tirzepatide, the active ingredient in Zepbound. Some, like Ivim, have stopped taking new patients.
&nbsp;
Mochi Health has no plans to stop, and neither do the four pharmacies it uses to supply patients with the medications, said Mochi CEO Myra Ahmad. The company uses a network of about 500 providers to write prescriptions for weight-loss drugs, including compounded versions. It's betting that offering personalized versions of the drugs will keep the company out of the crosshairs.&nbsp;
"It can be different dosing schedules … some patients prefer to go up in dosage much more slowly," Ahmad said. "Some patients like to mix a number of other medications into their compounded formulations, depending on the side effects that they're having. Some patients have side effects with any additives and brand name formulations. Compounding really opens up the door for so much personalization."&nbsp;
Amble, EllieMD and Willow didn't respond to CNBC's request for comment.&nbsp;
Compounding is where pharmacies mix ingredients of a drug to create a specialized version for specific patients. Say someone is allergic to a dye in a branded medication or needs a liquid form and the main manufacturer only sells capsules. In that case, the patient can turn to a compounded version.
When drugs are in shortage, they can be compounded in larger quantities to help fill the gap.&nbsp;
&nbsp;
Copycat versions of Lilly's Mounjaro and Zepbound and <a href="https://www.cnbc.com/quotes/NVO/">Novo Nordisk</a>'s Wegovy and Ozempic have been <a href="https://www.cnbc.com/2025/02/21/fda-shortage-of-novo-nordisks-wegovy-and-ozempic-drugs-is-resolved.html">widely available</a> in recent years because the U.S. Food and Drug Administration listed the brand versions as being in short supply.&nbsp;
That created a booming business for pharmacies compounding the highly popular class of weight loss and diabetes medications called <a href="https://www.cnbc.com/2024/05/14/healthy-returns-1-in-8-adults-have-taken-glp-1s-like-ozempic-survey.html">GLP-1s</a>.
But late last year, the FDA said all doses of Mounjaro and Zepbound were readily available and took the drug off its shortage list, spelling the end for mass compounding of the drug. After months of legal challenges, the FDA gave smaller pharmacies until early March to stop and larger pharmacies until this week before it started enforcing its rules.
The larger facilities aren't allowed to compound tirzepatide at all anymore. Smaller ones aren't supposed to make products that are essentially copies of a commercially available drug, a moniker with some wiggle room. The FDA sees essential copies as those that have a dosage within 10% of the commercially available drug or combine two or more commercially available drugs.
Mochi insists all of its prescriptions are personalized, including doses that differ from the standard Zepbound strengths. Other websites like EllieMD are advertising tirzepatide mixed with vitamin B12.&nbsp;
Scott Brunner, CEO of the Alliance for Pharmacy Compounding, said formulations or dosage strengths that aren't commercially available aren't considered a copy. However, combining two drugs into one — like adding vitamin B6 or B12 — would be considered a copy under a strict reading of FDA guidance.&nbsp;
"FDA guidance are pretty clear about what is and is not a copy," Brunner said. "And I would say any compounding pharmacy or outsourcing facility that continues to prepare copies of tirzepatide injection after today are putting themselves in a certain amount of legal risks."&nbsp;
John Herr, pharmacist and owner of Town &amp; Country Compounding Pharmacy, stopped compounding tirzepatide earlier this month. He didn't want to take the risk even though his 300 to 400 patients on it have been calling nonstop to complain about losing access.
Town &amp; Country, based in Ramsey, New Jersey, was charging patients about $200 a month — about one-fifth the list price for Zepbound and less than half the price Lilly charges self-paying patients.&nbsp;
What happens next is an open question. Enforcing the ban on mass compounding of tirzepatide mostly falls to the FDA. The agency didn't immediately respond to CNBC's request for comment.
Lilly can try to sue companies that continue, but it hasn't had much luck in the past. A Florida judge last year <a href="https://www.biospace.com/lilly-suffers-legal-loss-in-tirzepatide-case-against-compounding-pharmacy">dismissed</a> one of Lilly's cases, saying the company was trying to enforce a law that only the FDA can.&nbsp;
Ahmad, the CEO of Mochi, said she isn't worried about Lilly taking legal action against her providers. The way she sees it, they have established patient-physician relationships with the autonomy to decide how best to manage their patients.
The next two months will be informative. Mass compounding of <a href="https://www.cnbc.com/2025/02/21/fda-shortage-of-novo-nordisks-wegovy-and-ozempic-drugs-is-resolved.html">semaglutide</a> — the active ingredient in Novo Nordisk's Ozempic and Wegovy — needs to stop by the end of May, according to the FDA.
<a href="https://www.cnbc.com/quotes/HIMS/">Hims &amp; Hers Health</a> has already <a href="https://x.com/AndrewDudum/status/1896339552127824255">said</a> it will stop selling commercially available doses of semaglutide when the time comes. Customers who have a personalized dosing regimen will be able to continue without any change, the company added.&nbsp;

Biotech

'Zepbound Copycats Remain Online Despite FDA Ban' - CNBC

Trading Ideas

Live On CNBC, Steve Weiss Announces Bought More Bank Of America

What's the magic number for generational wealth? Is it $1 million? $10 million? More? The truth is, there isn't a one-size-fits-all answer. Wealth means different things to different people, but when it comes to passing down money that lasts for multiple generations, experts have <a href="https://www.benzinga.com/personal-finance/25/02/43539942/are-you-rich-heres-what-americans-think-you-need-to-be-considered-wealthy-2">attempted to put a number on it</a>.
According to some sources, the amount needed for generational wealth may actually be less than what most Americans think they need just to feel "rich."
Don't Miss:
<ul>
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> this is your last chance to become an investor for $0.80 per share.</a></li>
<li><a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.</li>
</ul>
<h2 class="wp-block-heading">How Much Do Americans Think It Takes to Be Wealthy?</h2>
<a href="https://www.aboutschwab.com/schwab-modern-wealth-survey-2024">Charles Schwab's 2024 Modern Wealth Survey</a> determined&nbsp; Americans now believe it takes $2.5 million to be considered wealthy. This figure has inched up from $2.2 million in 2023 and 2022, reflecting the impact of inflation and rising living costs.
Breaking it down by generation:
<ul>
<li>Boomers set the highest bar at $2.8 million</li>
<li>Gen X comes in at $2.7 million</li>
<li>Millennials and Gen Z believe the threshold is lower, though still in the millions</li>
</ul>
So, if Americans believe they need around $2.5 million just to be "rich," how much do experts say is needed to create lasting wealth that can be passed down for generations?
Trending: The secret weapon in billionaire investor portfolios that you almost certainly don't own yet. <a href="https://www.benzinga.com/money/masterworks">See which asset class has outpaced the S&amp;P 500 (1995-2024) – and with near-zero correlation.</a>
<h2 class="wp-block-heading">The $1.5 Million Per Child Benchmark</h2>
James McCarthy, an advisor with Nicola Wealth in Vancouver, suggests that generational wealth starts when an estate can comfortably provide at least $1.5 million per child, according to the <a href="https://financialpost.com/wealth/smart-money/how-much-money-do-you-need-to-have-generational-wealth">&nbsp;Financial Post</a>. While that number might not fund an extravagant lifestyle indefinitely, it can provide a meaningful financial foundation—especially when combined with smart investments and estate planning.
But that's on the lower end. Other experts suggest much higher figures.
<h2 class="wp-block-heading">The $10 Million Mark</h2>
According to <a href="https://www.financialsamurai.com/generational-wealth-angst-of-the-not-rich-enough-class/">Financial Samurai</a>, $10 million is the baseline for true generational wealth. Why? Because this amount can provide long-term financial security while allowing investments to continue growing. If managed wisely, $10 million can generate $300,000 to $500,000 in annual income, assuming a 3% to 5% withdrawal rate—enough to sustain a comfortable lifestyle without depleting the principal.
Trending: Have $200K saved?<a href="https://www.benzinga.com/money/have-200k-saved-heres-how-to-turn-it-into-lasting-wealth"> Here's how to turn it into lasting wealth</a>
<h2 class="wp-block-heading">The Estate Tax Exemption: A Benchmark for the Ultra-Wealthy</h2>
Some argue that generational wealth begins where estate taxes apply.
In 2025, the estate tax exemption is $13.99 million for individuals and $27.98 million for couples.
If your estate surpasses these limits, your heirs could face significant tax burdens—unless you've structured your wealth properly. In this view, generational wealth isn't just about a number but also about tax efficiency and strategic estate planning.
<h2 class="wp-block-heading">A More Attainable Figure? $5 Million Rule</h2>
Not everyone agrees that eight figures are necessary. <a href="https://wealthfactory.com/articles/how-much-is-generational-wealth/">Wealth Factory</a> suggests that a $5 million net worth can be enough to provide financial stability across generations. When diversified across real estate, investments, and cash, $5 million can sustain wealth over time—assuming future generations manage it wisely.
<h2 class="wp-block-heading">What Wealthy Americans Actually Plan to Pass Down</h2>
While expert opinions vary, how much are wealthy families actually leaving behind? According to a <a href="https://pressroom.aboutschwab.com/press-releases/press-release/2024/Generational-Wealth-Divide-Younger-High-Net-Worth-Americans-May-Reshape-How-Wealth-Is-Transferred-to-Future-Generations-According-to-New-Schwab-Survey/default.aspx">Charles Schwab survey</a> on generational wealth released in December, the average wealthy American expects to pass down $4.1 million in assets. Here's how it breaks down:
<ul>
<li>40% in real estate ($1.6 million)</li>
<li>31% in investments ($1.3 million)</li>
<li>18% in cash ($740,000)</li>
<li>11% from life insurance proceeds ($440,000)</li>
</ul>
For ultra-high-net-worth individuals (those with $10 million or more in investable assets), the number jumps to $11.9 million, with some even fearing they may be leaving too much behind.
See Also: How do billionaires pay less in income tax than you?<a href="https://www.benzinga.com/money/tax-deferring-adv"> Tax deferring is their number one strategy</a>.
<h2 class="wp-block-heading">Beyond the Numbers: Real Estate, Investments, and Estate Planning</h2>
Generational wealth isn't just about a lump sum of cash. Many families pass down wealth in the form of:
<ul>
<li>Real estate – Primary homes, rental properties, and commercial buildings</li>
<li>Businesses – Family-run enterprises that continue generating income</li>
<li>Investments – Stocks, mutual funds, and other assets that appreciate over time</li>
<li>Life insurance – Providing a financial safety net for heirs</li>
</ul>
One major takeaway from the Schwab generational wealth survey? Estate planning is crucial. While 57% of wealthy Americans have a will, far fewer have a trust (34%), which could help minimize taxes and protect wealth. More than half (56%) <a href="https://www.benzinga.com/money/are-you-rich">work with a financial advisor</a>, proving that maintaining generational wealth takes more than just a large bank balance.
<h2 class="wp-block-heading">What's the Right Number for You?</h2>
There's no universal answer to what qualifies as generational wealth, but one thing is clear—it's about more than just a dollar amount. A solid financial plan, diversified assets, and smart estate planning matter just as much as the <a href="https://www.benzinga.com/money/smartasset">size of your nest egg</a>.
So, while many Americans dream of hitting the $2.5 million "wealthy" threshold, building lasting wealth for future generations requires a bigger plan—one that goes beyond just having money to spend.
Read Next:
<ul>
<li>It&#8217;s no wonder Jeff Bezos holds over $250 million in art — <a href="https://www.benzinga.com/money/masterworks">this alternative asset has outpaced the S&amp;P 500 since 1995, delivering an average annual return of 11.4%. Here&#8217;s how everyday investors are getting started.</a></li>
<li>Can you guess how many Americans successfully retire with $1,000,000 saved?<a href="https://www.benzinga.com/money/1milsaved"> The percentage may shock you</a>.</li>
</ul>

Personal Finance

Can You Guess How Much You Need to Build Generational Wealth? Some Say It's Less Than What It Takes to Feel 'Rich'

The Association of the British Pharmaceutical Industry (ABPI) is urging ministers to address excessive levies on manufacturers to ensure the sector remains competitive globally.
The life sciences industry, a key pillar of the UK&#8217;s economic strategy, could struggle to attract investment unless payment rates are adjusted.
Last week, the government <a href="https://www.abpi.org.uk/media/news/2025/march/uk-set-to-demand-a-third-of-pharmaceutical-company-revenue-in-second-half-of-2025/" target="_blank" rel="noreferrer noopener">proposed</a> raising the Statutory Scheme payment rate for newer branded medicines from 15.5% to 32.2% of subject companies&#8217; National Health Service (NHS) sales in the second half of 2025.
The payment rate is the revenue companies must hand back to the government on their sales of branded medicines to the NHS. It is an additional charge to the taxes paid by companies.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/03/44362710/uk-pharma-industry-trade-association-restores-wegovyozempic-maker-novo-nordisks-membership-after-two-years-of-suspension" rel="noreferrer noopener">UK Pharma Industry Trade Association Restores Wegovy/Ozempic Maker Novo Nordisk&#8217;s Membership After 2 Years Of Suspension</a>
UK pharmaceutical leaders from Amgen Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), AstraZeneca Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>), Biogen Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>), Boehringer Ingelheim, Bristol Myers Squibb &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>), Daiichi Sankyo Ltd (OTC:<a class="ticker" href="https://www.benzinga.com/stock/DSNKY#OTC">DSNKY</a>), Gilead Sciences Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>), Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), Merck &amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), Novartis AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>), Pfizer Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), Roche Holdings AG (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>), Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>), Takeda Pharmaceutical Co Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAK#NYSE">TAK</a>) and UCB SA (OTC:<a class="ticker" href="https://www.benzinga.com/stock/UCBJY#OTC">UCBJY</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/UCBJF#OTC">UCBJF</a>) point to the challenges to investing in the U.K.
The pharmaceutical sector <a target="_blank" href="https://www.abpi.org.uk/media/news/2025/march/medicine-levy-makes-the-uk-un-investable-say-pharma-leaders/" rel="noreferrer noopener">contributes</a> over 17.6 billion pounds ($22.76 billion) directly to the U.K. economy, with an additional 45 billion generated through research and development spillovers.
However, companies argue that growth is being stifled due to escalating mandatory payments. Under the current system, firms must pay between 23.5% and 35.6% of their branded medicine sales revenue to the NHS. This is significantly higher than other European nations, where comparable rates range from 5.7% to 9%, ABPI writes.
The ABPI report highlights that while the UK once led in medicine availability, it has slipped to ninth place in Europe over the past decade. One year after launch, medicine usage in England is only 52% of the average of comparable nations, rising to 62% after five years.
Additionally, the UK has dropped from fourth to tenth in global rankings for phase 3 clinical trials, lagging behind Spain, Germany and Italy.
Investment in UK pharmaceutical research has also declined, with the country&#8217;s share of global R&amp;D investment falling from 7.3% to 5.7% in just three years.
This marks the fastest decline of any European G7 nation. Meanwhile, NHS funding has grown by 33% in real terms over the past decade, but spending on branded medicines has been capped at annual growth rates between 1.1% and 2%, declining by 11% when adjusted for inflation.
The industry and government have long collaborated on agreements to ensure NHS access to medicines.
The latest, the Voluntary Scheme for Branded Medicines, Pricing, Access, and Growth (VPAG), was intended to realign UK payment rates with international standards. While rates for newer medicines briefly dropped to 15.1% in 2024, they surged again in 2025 to 23.5% for newer medicines, with companies still paying 10.6%-35.6% for older products.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/03/44436766/is-freeport-mcmorans-us-based-footprint-an-advantage-analyst-upgrades-stock-amid-copper-import-tariff-risk" target="_blank" rel="noreferrer noopener">Is Freeport-McMoRan&#8217;s US-Based Footprint An Advantage? Analyst Upgrades Stock Amid Copper Import Tariff Risk</a></li>
</ul>
Photo: Shutterstock

Government

Large Cap

Eurozone

Health Care

AMGN

BIIB

DSNKY

GILD

RHHBY

UCBJF

UCBJY

Pharmaceutical Firms Say UK Investment Is 'Unlikely' Unless Payment Levy Is Adressed

RBC Capital analyst Piral Dadhania maintains Nike (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) with a Sector Perform and lowers the price target from $67 to $66.

RBC Capital Maintains Sector Perform on Nike, Lowers Price Target to $66

Darden Restaurants Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRI#NYSE">DRI</a>) reported its third-quarter earnings yesterday. Sales of $3.158 billion <a href="https://www.benzinga.com//node/44416210">missed the consensus estimate.</a>
The following are the comments from different analysts regarding the company&#8217;s performance.
Oppenheimer analyst Brian Bittner reiterated an Outperform rating on the shares and raised the <a href="https://www.benzinga.com/quote/DRI/analyst-ratings">price forecast from $218.00 to $230.00.</a>
The analyst is optimistic that DRI&#8217;s fiscal 2026 will provide catalysts for growth, surpassing conservative Street expectations. Following a mixed third quarter, same-store sales trends for the fourth quarter have picked up, now exceeding 3% (compared to the Street&#8217;s 2.5%), even before the implementation of enhanced marketing efforts tied to Olive Garden&#8217;s new delivery service.
After a thorough review of the model, the analyst has slightly raised the EPS projections through 2026E (25E/&#8217; 26E EPS to $9.50/$10.77 from $9.48/$10.74), with the potential for further upward revisions.
The analyst notes that a combination of new sales drivers and overly cautious margin projections will set the stage for positive revisions in the next 12 months.
Also Read:<a target="_blank" href="https://www.benzinga.com/markets/equities/25/03/44434720/defense-secretary-slashes-580-million-in-wasteful-spending-targets-overdue-overpriced-projects" rel="noreferrer noopener"> Defense Secretary Slashes $580 Million In Wasteful Spending—Targets Overdue, Overpriced Projects</a>
Wedbush analyst Nick Setyan reiterated an Outperform rating on the shares and raised the price target from $220.00 to $235.00.
Despite weather-related challenges affecting same-store sales growth, EPS showed upside, said the analyst.
The analyst notes the upper range of EPS guidance is achievable. The fourth-quarter EPS guidance is $2.88–2.95, compared to the consensus of $2.93.
With expected commodity inflation around 3%, labor inflation around 3.5%, menu pricing increases of approximately 2% at Olive Garden and 3% at LongHorn, and visibility for additional SSS growth, the analyst considers the higher end of the EPS range realistic.
TD Securities analyst Andrew Charles&nbsp;reiterated a Hold rating on the shares and raised the price forecast from $180.00 to $190.00.
Darden&#8217;s shares reacted positively to the fourth-quarter same-store sales guidance of 3%+, which is currently tracking at that level.
The company is benefiting from a spring rebound in full-service dining after weather-impacted months. However, given soft consumer sentiment, the analyst is less confident in the rebound&#8217;s longevity.
The analyst seeks more proof that Darden&#8217;s strategies to boost Olive Garden will lead to market share growth despite the premium valuation of its shares.
While the <a target="_blank" href="https://www.benzinga.com//node/44417951" rel="noreferrer noopener">Uber Direct partnership </a>is contributing a 1%-1.25% lift to Olive Garden&#8217;s SSS, the peak 13x FY2 EV/EBITDA suggests a $230/share price, indicating a better risk/reward opportunity in other sector stocks.
Stephens &amp; Co. analyst Jim Salera reiterated an Equal Weight on the shares and raised the price forecast from $175.00 to $178.00.
Darden reported same-store sales below expectations but beat on adjusted EPS. Weather and holiday timing would have resulted in a sales beat, said the analyst.
Investors were encouraged by Darden reaffirming its FY25 same-store sales guidance, supported by strong March trends.
While the analyst remains positive on the company&#8217;s operational execution and scale, the current valuation is fully priced.
Price Action: DRI shares traded higher by 0.32% at $199.65 at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44420034/d-waves-new-blockchain-architecture-could-slash-energy-usage-by-1000x" target="_blank" rel="noreferrer noopener">D-Wave Unveils New Blockchain Architecture To Slash Energy Usage</a></li>
</ul>
Photo by Sundry Photography via Shutterstock.

Analyst Color

Equities

Reiteration

Darden Restaurants Olive Garden Growth Drive Optimism Amid Valuation Concerns: Analyst

General Motors's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) short percent of float has risen 69.83% since its last report. The company recently reported that it has 42.80 million shares sold short, which is 5.01% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.02 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>General Motors Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742574626_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for General Motors has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing General Motors's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, General Motors's peer group average for short interest as a percentage of float is 5.62%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

What's Driving the Market Sentiment Around General Motors?

Robinhood Markets's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NYSE">HOOD</a>) short percent of float has risen 9.9% since its last report. The company recently reported that it has 23.92 million shares sold short, which is 3.33% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.0 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Robinhood Markets Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742574621_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Robinhood Markets has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Robinhood Markets's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Robinhood Markets's peer group average for short interest as a percentage of float is 3.23%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

HOOD

Looking Into Robinhood Markets's Recent Short Interest

Strategy's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NYSE">MSTR</a>) short percent of float has risen 11.95% since its last report. The company recently reported that it has 25.67 million shares sold short, which is 10.68% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.39 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Strategy Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742574616_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Strategy has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Strategy's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Strategy's peer group average for short interest as a percentage of float is 2.61%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

MSTR

Looking Into Strategy's Recent Short Interest

RTX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RTX#NYSE">RTX</a>) has outperformed the market over the past 5 years by 1.13% on an annualized basis producing an average annual return of 19.34%. Currently, RTX has a market capitalization of $178.38 billion. 
Buying $100 In RTX: If an investor had bought $100 of RTX stock 5 years ago, it would be worth $280.26 today based on a price of $133.61 for RTX at the time of writing.
<h3>RTX's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742574609_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $100 In This Stock 5 Years Ago, You Would Have This Much Today

U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling around 0.1% on Friday.
The Dow traded down 0.20% to 41,868.48 while the NASDAQ dipped 0.06% to 17,681.21. The S&amp;P 500 also fell, dropping, 0.28% to 5,647.20.
Check This Out: <a href="https://www.benzinga.com/25/03/44434941/how-to-earn-500-a-month-from-kb-home-stock-ahead-of-q1-earnings">How To Earn $500 A Month From KB Home Stock Ahead Of Q1 Earnings</a>
Leading and Lagging Sectors Communication services shares rose by 0.3% on Friday.
In trading on Friday, materials shares dipped by 1.8%.
Top Headline
Shares of Micron Technology Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) fell more than 6% on Friday after the company reported second-quarter financial results.
Micron reported second-quarter revenue of $8.05 billion, beating the consensus estimate of $7.89 billion. Total revenue was up from $5.82 billion on a year-over-year basis. The company reported second-quarter adjusted earnings of $1.56 per share, beating analyst estimates of $1.42 per share, according to Benzinga Pro.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Ouster, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OUST#NASDAQ">OUST</a>) shares shot up 25% to $10.51 after the company reported better-than-expected quarterly financial results.</li>
<li>Shares of Scholastic Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCHL#NASDAQ">SCHL</a>)got a boost, surging 15% to $21.66 following upbeat quarterly earnings.</li>
<li>Allurion Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALUR#NASDAQ">ALUR</a>) shares were also up, gaining 39% to $3.1593 after the company announced results from its allurion program and low-dose GLP-1 therapy combination.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Damon Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DMN#NASDAQ">DMN</a>) shares dropped 70% to $0.0376 after the company announced a $16.5 million public offering.</li>
<li>Shares of Planet Labs PBC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PL#NYSE">PL</a>) were down 19% to $3.4350 after the company reported worse-than-expected fourth-quarter financial results.</li>
<li>TELA Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TELA#NASDAQ">TELA</a>) was down, falling 35% to $1.51 after the company reported worse-than-expected quarterly financial results. Additionally, Piper Sandler downgraded the stock from Overweight to Neutral and cut its price target from $5 to $2.</li>
</ul>
Commodities In commodity news, oil traded down 0.2% to $67.94 while gold traded down 1.1% at $3,011.10.
Silver traded down 1.7% to $33.400 on Friday, while copper fell 1.2% to $5.0525.
Euro zone
European shares were mostly lower today. The eurozone's STOXX 600 fell 0.98%, Germany's DAX 40 fell 1.15% and France's CAC 40 fell 1.01%. Spain's IBEX 35 Index rose 0.05%, while London's FTSE 100 slipped 0.95%.
Asia Pacific Markets
Asian markets closed mostly lower on Friday, with Japan's Nikkei 225 falling 0.20%, China's Shanghai Composite Index falling 1.29%, Hong Kong's Hang Seng Index dipped 2.19% and India's BSE Sensex gaining 0.73%.
Economics
The Baker Hughes oil rig count report will be released today.
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/03/44436119/tesla-to-410-here-are-10-top-analyst-forecasts-for-friday">Tesla To $410? Here Are 10 Top Analyst Forecasts For Friday</a></li>
</ul>

Earnings

Commodities

Markets

ALUR

OUST

SCHL

TELA

Gold Down Over 1%; Micron Technology Shares Fall After Q2 Earnings

RBC Capital analyst Luca Issi maintains Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Outperform and raises the price target from $310 to $330.

ALNY

RBC Capital Maintains Outperform on Alnylam Pharmaceuticals, Raises Price Target to $330

JP Morgan analyst Melissa Wedel maintains Runway Gwth Fin (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RWAY#NASDAQ">RWAY</a>) with a Neutral and lowers the price target from $11 to $10.5.

RWAY

JP Morgan Maintains Neutral on Runway Gwth Fin, Lowers Price Target to $10.5

Mizuho analyst Ben Chaiken maintains Six Flags Entertainment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FUN#NYSE">FUN</a>) with a Outperform and lowers the price target from $54 to $49.

Mizuho Maintains Outperform on Six Flags Entertainment, Lowers Price Target to $49

KB Home (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KBH#NYSE">KBH</a>) will release its first-quarter financial results, after the closing bell, on <a href="https://www.benzinga.com/quote/KBH/earnings">Monday, March 24</a>.
Analysts expect the company to report quarterly earnings at $1.58 per share, down from $1.76 per share in the year-ago period. KB Home projects quarterly revenue of $1.50 billion, compared to $1.47 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On Jan. 23, the company's board of directors declared a quarterly cash dividend of 25 cents per share on its common stock.
KB Home shares fell 0.4% to close at $61.27 on Thursday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/KBH/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li>Seaport Global analyst Kenneth Zener upgraded the stock from Neutral to Buy with a price target of $79 on March 6, 2025. This analyst has an accuracy rate of 72%.</li>
<li>B of A Securities analyst Rafe Jadrosich maintained a Neutral rating and cut the price target from $76 to $71 on Jan. 27, 2025. This analyst has an accuracy rate of 65%.</li>
<li>Raymond James analyst Buck Horne reiterated an Outperform rating and slashed the price target from $93 to $80 on Jan. 21, 2025. This analyst has an accuracy rate of 71%.</li>
<li>Keefe, Bruyette &amp; Woods analyst Jade Rahmani maintained a Market Perform rating and cut the price target from $85 to $76 on Jan. 17, 2025. This analyst has an accuracy rate of 67%.</li>
<li>JP Morgan analyst Michael Rehaut maintained a Neutral rating and cut the price target from $82 to $74.5 on Jan. 15, 2025. This analyst has an accuracy rate of 72%.</li>
</ul>
Considering buying KBH stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="570" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/21055619/image-189-1024x570.png" alt="" class="wp-image-835482" style="width:544px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/21055619/image-189-1024x570.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/21055619/image-189-300x167.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/21055619/image-189-768x428.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/21055619/image-189.png 1126w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/03/44414749/top-2-defensive-stocks-that-may-keep-you-up-at-night-in-march">Top 2 Defensive Stocks That May Keep You Up At Night In March</a></li>
</ul>

KB Home Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

RBC Capital analyst Daniel Perlin maintains Accenture (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACN#NYSE">ACN</a>) with a Outperform and lowers the price target from $399 to $392.

RBC Capital Maintains Outperform on Accenture, Lowers Price Target to $392

JP Morgan analyst Matthew Boss maintains Nike (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) with a Neutral and lowers the price target from $73 to $64.

JP Morgan Maintains Neutral on Nike, Lowers Price Target to $64

Press Releases

Frontier Releases New Study That Reveals Fiber Deployment Can Boost the U.S. Economy by Over $3 Trillion

Johnson Fistel Investigates the Proposed Merger of Frontier Communications; Is $38.50 a Fair Price?

Frontier Offers Customers Netflix Premium Plan Just in Time for the Holiday Season

Frontier to Report Fourth-Quarter and Full-Year 2024 Earnings on Feb. 20, 2025

Frontier Reports Fourth-Quarter and Full-Year 2024 Results

FYBR

ATN International

Chunghwa Telecom

Frontier Comms Parent Inc

IHS Holding

Shenandoah Telecommunications Co - Common Stock

Shenandoah

Sunrise Communications AG - American Depositary Shares representing Class A shares

Sunrise Communications

AT&T

Telefonica

Telecom Argentina

Telkom Indonesia

Telefonica Brasil S.A. American Depositary Shares (Each representing One Common Share)

Comments

Frontier Comms Parent Inc

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL